William Link - Glaukos Corp Independent Chairman of the Board
| GKOS Stock | USD 142.94 1.06 0.74% |
Chairman
Dr. William J. Link, Ph.D., is an Independent Chairman of the Board of Glaukos CorporationrationrationDr. Link has also been a member of the board of directors of DOSE Medical Corporation since October 2009. Dr. Link has a proven record of building and operating large, successful medical product companies. He has extensive knowledge of medical devices and drug delivery, particularly in ophthalmology, and his operating experience spans 25 years in general management in the healthcare industry. Dr. Link is a managing director and cofounder of Versant Ventures Management LLC, a VC firm investing in early stage healthcare companies. Prior to cofounding Versant Ventures in 1999, Dr. Link was a general partner at Brentwood VC. From 1986 to 1997, Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corporation . He also founded and served as President of American Medical Optics, Inc. . Dr. Link served as a director of Advanced Medical Optics, Inc. from 2002 to 2009 and a director of Inogen, Inc. from 2003 to February 2014. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. He was a member of the board of directors of Edwards Lifesciences Corporation since May 2009 and Second Sight Medical Products, Inc. since 2004 since 2001.
| Age | 74 |
| Tenure | 23 years |
| Address | One Glaukos Way, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0774) % which means that it has lost $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.261) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.16 in 2024. At this time, Glaukos Corp's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 22.4 M in 2024, whereas Other Assets are likely to drop slightly above 15.3 M in 2024.Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| William Kozy | LivaNova PLC | 72 | |
| Frank Laukien | Bruker | 64 | |
| Bill Sanford | Integer Holdings Corp | 76 | |
| Curt Hartman | CONMED | 60 | |
| D Grossman | Nevro Corp | 59 | |
| DKeith Grossman | Nevro Corp | 64 | |
| Mark Tryniski | CONMED | 60 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mory Gharib, CoFounder | ||
| Gilbert Kliman, Independent Director | ||
| Michele Allegretto, Senior Resources | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Robert Davis, General VP | ||
| Diane Biagianti, Sr Counsel | ||
| David Hoffmeister, Independent Director | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Denice Torres, Independent Director | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Tomas Navratil, Chief Development Officer | ||
| MD FACS, Chief Officer | ||
| Jane Rady, Senior Development | ||
| Aimee Weisner, Independent Director | ||
| Robert JD, General VP | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 7.83 B | ||||
| Shares Outstanding | 55.14 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 96.81 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Earning | 94.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.